Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Peripheral T-Cell Lymphomas (PTCL) Overview 9 Therapeutics Development 10 Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview 10 Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies 11 Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies 16 Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development 18 AB Science SA 18 Affimed Therapeutics AG 19 Bayer AG 20 Celgene Corporation 21 CerRx, Inc. 22 Chipscreen Biosciences Ltd 23 Eisai Co., Ltd. 24 Incyte Corporation 25 Johnson & Johnson 26 Karyopharm Therapeutics, Inc. 27 Mundipharma International Ltd 28 Ono Pharmaceutical Co., Ltd. 29 Onxeo SA 30 Pfizer Inc. 31 Rhizen Pharmaceuticals S.A. 32 Seattle Genetics, Inc. 33 Solasia Pharma K.K. 34 Spectrum Pharmaceuticals, Inc. 35 TG Therapeutics, Inc. 36 Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Target 38 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 AFM-13 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 belinostat - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 brentuximab vedotin - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 copanlisib hydrochloride - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 CS-055 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 darinaparsin - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 denileukin diftitox - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 fenretinide - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 forodesine hydrochloride - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 lenalidomide - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 masitinib - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 mitoxantrone hydrochloride - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 nivolumab - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 NL-101 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 pralatrexate - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 romidepsin - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 RP-6530 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 ruxolitinib phosphate - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 selinexor - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 SH-7129 - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 114 temsirolimus - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 TGR-1202 - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 tipifarnib - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 Peripheral T-Cell Lymphomas (PTCL) - Recent Pipeline Updates 124 Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects 213 Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products 214 Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones 215 Featured News & Press Releases 215 Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 215 Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015 215 Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP 217 Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma 218 Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma 220 Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology 220 May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3 221 Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China 223 Dec 09, 2014: Combination of ISTODAX (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma 223 Dec 05, 2014: Spectrum Pharmaceuticals Highlights Abstracts on Beleodaq (belinostat) at the 56th Annual Meeting of the ASH in San Francisco 224 Appendix 225 Methodology 225 Coverage 225 Secondary Research 225 Primary Research 225 Expert Panel Validation 225 Contact Us 225 Disclaimer 226

List of Tables Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016 10 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Development by Companies, H1 2016 (Contd..1) 17 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science SA, H1 2016 18 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed Therapeutics AG, H1 2016 19 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H1 2016 20 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H1 2016 21 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CerRx, Inc., H1 2016 22 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H1 2016 23 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H1 2016 24 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H1 2016 25 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Johnson & Johnson, H1 2016 26 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 27 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Ltd, H1 2016 28 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 29 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H1 2016 30 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pfizer Inc., H1 2016 31 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 32 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Seattle Genetics, Inc., H1 2016 33 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H1 2016 34 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 35 Peripheral T-Cell Lymphomas (PTCL) - Pipeline by TG Therapeutics, Inc., H1 2016 36 Assessment by Monotherapy Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Mechanism of Action, H1 2016 42 Number of Products by Stage and Route of Administration, H1 2016 44 Number of Products by Stage and Molecule Type, H1 2016 46 Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Recent Pipeline Updates, H1 2016 124 Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H1 2016 213 Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H1 2016 214 List of Figures Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Products, H1 2016 15 Assessment by Monotherapy Products, H1 2016 37 Number of Products by Top 10 Targets, H1 2016 38 Number of Products by Stage and Top 10 Targets, H1 2016 38 Number of Products by Top 10 Mechanism of Actions, H1 2016 41 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 41 Number of Products by Routes of Administration, H1 2016 43 Number of Products by Stage and Routes of Administration, H1 2016 43 Number of Products by Molecule Types, H1 2016 45 Number of Products by Stage and Molecule Types, H1 2016 45

AB Science SA Affimed Therapeutics AG Bayer AG Celgene Corporation CerRx, Inc. Chipscreen Biosciences Ltd Eisai Co., Ltd. Incyte Corporation Johnson & Johnson Karyopharm Therapeutics, Inc. Mundipharma International Ltd Ono Pharmaceutical Co., Ltd. Onxeo SA Pfizer Inc. Rhizen Pharmaceuticals S.A. Seattle Genetics, Inc. Solasia Pharma K.K. Spectrum Pharmaceuticals, Inc. TG Therapeutics, Inc.